title: Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
abstract: Advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the efficient targeting of mutated neoantigens for personalized cancer vaccination. Due to their absence during negative selection of T cells and their lack of expression in healthy tissue, tumor mutations are considered as optimal targets for cancer immunotherapy. Preclinical and early clinical data suggest that synthetic mRNA can serve as potent drug format allowing the cost efficient production of highly efficient vaccines in a timely manner. In this review, we describe a process, which integrates next generation sequencing based cancer mutanome mapping, in silico target selection and prioritization approaches, and mRNA vaccine manufacturing and delivery into a process we refer to as MERIT (mutanome engineered RNA immunotherapy).
authors: Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, Germany; Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131 Mainz, Germany.
authors: Mathias
authors: M
authors: Vormehr
authors: TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.
authors: Barbara
authors: B
authors: Schrörs
authors: TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.
authors: Sebastian
authors: S
authors: Boegel
authors: TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.
authors: Martin
authors: M
authors: Löwer
authors: TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.
authors: Özlem
authors: Ö
authors: Türeci
authors: Research Center for Immunotherapy (FZI), Langenbeckstr. 1, Building 708, 55131 Mainz, Germany; Biopharmaceutical New Technologies (BioNTech) Corporation, An der Goldgrube 12, 55131 Mainz, Germany; TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, Freiligrathstr. 12, 55131 Mainz, Germany.
authors: Ugur
authors: U
authors: Sahin
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D005818:Genetic Engineering; D016678:Genome / Q000276:immunology; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D007167:Immunotherapy; D009154:Mutation / Q000235:genetics; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D018802:Patient-Centered Care; D012333:RNA, Messenger
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D012333:RNA, Messenger